Paratek & Project BioShield

This week Dr. Evan Loh, Paratek CEO, returns to Off theShelf to share the latest in the biopharmaceutical company’s partnership with the Biomedical Advanced Research and Development Authority’s (BARDA’s) Project BioShield.

Paratek’s antibiotic, NUZYRA (omadacycline) has been designated “an essential” medicine by the FDA, and Loh provides an update on the progress made in onshoring of manufacturing of NUZYRA, from the production of API through finished drug product for both IV and oral formulations.

Loh shares the journey to domestic manufacturing, highlighting the critical role Paratek’s public-private partnership with BARDA played in developing manufacturing capability. Antimicrobial resistance (AMR) along with biological threat actors are continuing and growing threat and Loh discusses the current environment and the key policy considerations in combatting these and other healthcare threats.

Finally, Loh talks about the potential that the results from the successful development of treatments through public-partnerships have the potential to be leveraged to support/protect the warfighter.

Learn more about your ad choices. Visit podcastchoices.com/adchoices